Drug Profile
Research programme: small molecule anti-cancer therapeutics - Peloton Therapeutics
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Peloton Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors; Protein interaction domain and motif inhibitors; Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Cancer in USA (PO)
- 30 Jul 2019 Peloton Therapeutics has been acquired by Merck & Co
- 07 Mar 2018 Early research in Cancer in USA (PO) (Peloton Therapeutics pipeline, March 2018)